|
Jun 4
|
ONVO Increases Cash and Improves Prospects
|
|
May 21
|
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
|
|
May 14
|
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
|
|
May 9
|
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
|
|
May 1
|
ONVO Announces Very Positive Phase 2 Results
|
|
Apr 15
|
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
|
|
Mar 29
|
Top 15 3D Printing Companies in the US
|
|
Feb 10
|
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Feb 9
|
ONVO Continues Progress
|
|
Jan 9
|
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
|
|
Dec 6
|
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
|